ESMO: New Agent Active in Advanced Ovarian Cancer, Dana-Farber Cancer Institute Study

Published: Oct 15, 2010

MedPageToday -- MILAN -- A quarter of patients with platinum-refractory or resistant ovarian cancer had a good response to an investigational agent that targets a kinase implicated in oncogenesis and tumor progression, results from a small preliminary clinical trial showed.

Back to news